Wealth Enhancement Advisory Services
TEVA icon

Wealth Enhancement Advisory Services’s Teva Pharmaceuticals TEVA Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$621K Buy
18,842
+10,580
+128% +$352K ﹤0.01% 2481
2026
Q1 		$249K Sell
8,262
-3,649
-31% -$117K ﹤0.01% 2955
2025
Q4 		$382K Buy
11,911
+379
+3% +$9.34K ﹤0.01% 2704
2025
Q3 		$231K Buy
+11,532
New +$203K ﹤0.01% 3000

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Wealth Enhancement Advisory Services's TEVA Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its Teva Pharmaceuticals (TEVA) stake by 128% in Q2 2026, buying an estimated $352K and bringing the position to 18,842 shares worth $621K. The position accounts for ﹤0.01% of the portfolio, ranked #2481.

Wealth Enhancement Advisory Services first reported a position in TEVA in Q3 2025 and has held it in 4 quarters since. 676 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Wealth Enhancement Advisory Services held 18,842 shares of Teva Pharmaceuticals worth $621K as of Q2 2026.
  • Wealth Enhancement Advisory Services bought 10,580 Teva Pharmaceuticals shares in Q2 2026, an estimated $352K.
  • Teva Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #2481 holding.
  • Wealth Enhancement Advisory Services first reported a position in Teva Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 676 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.